Drug profile · INN
ponatinib
ICLUSIG
ponatinib (ICLUSIG) is a bcr/abl fusion protein inhibitor. Associated with Lacuna Pharma Pty Ltd.
EMA: approved TGA: approved NMPA: clinical trials Antineoplastic and immunomodulating agents (L01) L01EA05
Patents linked 0
Pipeline programs 18
News articles 0
Drug details — ponatinib
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 18
- Data quality
- 0.83
Quick answer
ponatinib (ICLUSIG) is a bcr/abl fusion protein inhibitor. Associated with Lacuna Pharma Pty Ltd.
Key facts
INN ponatinib
Brand ICLUSIG
Mechanism Bcr/Abl fusion protein inhibitor
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01EA05
Originator Lacuna Pharma Pty Ltd
Mechanism of action
Bcr/Abl fusion protein inhibitor
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is ponatinib?
ponatinib (ICLUSIG) is a bcr/abl fusion protein inhibitor. Associated with Lacuna Pharma Pty Ltd.
What is the brand name for ponatinib?
ICLUSIG is a marketed brand name for ponatinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.